IOMERVU

Growth

iomeprol

NDAINTRAVENOUSSOLUTION

Approved

Nov 2024

Lifecycle

Growth

Competitive Pressure

18/100

Loss of Exclusivity

LOE Date

Nov 27, 2029

45 months away

Exclusivity Expiry

Nov 27, 2029

Company

External Resources

Full prescribing information

FDA approval history

Drug nomenclature & identifiers